SKN | Wells Fargo Cuts Soleno Therapeutics Target to $110 While Maintaining Overweight

Key Takeaways

• Wells Fargo lowers its price target on Soleno Therapeutics, Inc. to $110 from $114 but reiterates Overweight.
• Management commentary reduced expectations of a near-term acquisition scenario.
• Strong Vykat XR sales and profitability achieved in fiscal 2025.
• Analysts see shares as inexpensive relative to projected FY26 revenue and cash flow.

Target Trim Reflects Strategic Recalibration

Wells Fargo reduced its price target modestly to $110, citing management’s emphasis on building a broader pipeline and extending lifecycle management for Vykat XR rather than positioning the company for a near-term takeout.

The departure of the company’s CFO also contributed to some near-term uncertainty. However, Wells Fargo stated that shares remain attractively valued relative to expected fiscal 2026 revenue and cash flow generation.

The maintained Overweight rating signals continued conviction despite the slight downward revision.

Diverging Analyst Targets

TD Cowen took a more conservative approach, cutting its target to $85 from $120 while keeping a Buy rating.

The firm pointed to strong fourth-quarter sales performance for Vykat XR and reaffirmed expectations for commercial momentum in 2026. Management anticipates approximately 1,000 new patient start forms over the next nine to twelve months, supporting revenue visibility.

Earnings Snapshot

Soleno reported Q4 revenue of $91.7 million from Vykat XR and full-year 2025 revenue of $190.4 million.

The company generated $48.7 million in operating cash flow in the fourth quarter and posted positive net income of $20.9 million for the year, marking a transition to profitability.

The earnings profile reinforces a narrative shift from clinical-stage development toward commercial execution.

Business Positioning

Soleno Therapeutics focuses on therapies for rare neurobehavioral and metabolic disorders. Its lead candidate, Diazoxide Choline Controlled-Release (DCCR), is designed to treat Prader-Willi Syndrome.

The company’s growing commercial base for Vykat XR strengthens its revenue foundation while management explores pipeline expansion and lifecycle extensions.

Outlook

The slight reduction in Wells Fargo’s price target appears driven by strategic positioning rather than operational weakness.

With profitability achieved and cash flow turning positive, investor focus will likely center on sustained commercial uptake, pipeline expansion, and clarity around capital allocation priorities.

For confidential discussions regarding rare-disease biotech valuation frameworks, commercial ramp modeling for specialty therapeutics, lifecycle management strategy assessment, and risk-adjusted revenue projections within small-cap biopharmaceutical portfolios, our senior advisory team is available for discreet consultation tailored to institutional and cross-border mandates.